2',3'-Dideoxyadenosine is selectively toxic for TdT-positive cells

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• 2',3'-dideoxynucleosides (ddNs) are evaluated as antiretroviral agents for HIV.
• ddNs inhibit HIV replication by terminating DNA chain elongation via reverse transcriptase.
• ddNs can also inhibit terminal deoxynucleotidyl transferase (TdT), a DNA polymerase found in lymphoid cells.

Purpose of the Study:

• To investigate the cytotoxic effects of 2',3'-dideoxyadenosine (ddA) on TdT-positive cells.
• To determine if TdT mediates intracellular chain termination by ddA metabolites.
• To explore the potential therapeutic applications of ddA in TdT-positive malignancies.

Main Methods:

• Exposure of TdT-positive and TdT-negative cell lines to ddA and Coformycin (CF).
• Assessment of cytotoxicity in cell lines with varying TdT expression levels.
• Ex vivo treatment of fresh leukemic cells (TdT-positive and TdT-negative) with ddA/CF.

Main Results:

• ddA induced dose-related cytotoxicity in TdT-positive cell lines, enhanced by CF.
• TdT-positive cells exhibited significantly higher cell death (90%) compared to TdT-negative cells (30%) after ddA/CF exposure.
• Ex vivo treatment demonstrated selective ddA/CF cytotoxicity against TdT-positive acute lymphocytic leukemia cells.

Conclusions:

• ddA, in combination with CF, selectively induces cell death in TdT-positive cells.
• The mechanism likely involves intracellular chain termination by ddAMP mediated by TdT.
• This selective cytotoxicity suggests potential therapeutic relevance for ddA/CF in TdT-positive cancers.